Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer.

Cancer Care Delivery Research: Building the Evidence Base to Support Practice Change in Community Oncology. J Clin Oncol (2015) 1.03

Extreme oncoplasty: breast conservation for patients who need mastectomy. Breast J (2015) 1.01

In regard to Moran et al. Int J Radiat Oncol Biol Phys (2014) 0.97

SSO-ASTRO consensus guidelines for breast-conserving surgery with whole-breast radiation: in regard to Moran et al. Int J Radiat Oncol Biol Phys (2014) 0.96

Systematization of Oncoplastic Surgery: Selection of Surgical Techniques and Patient-Reported Outcome in a Cohort of 1,035 Patients. Ann Surg Oncol (2015) 0.88

Increased Risk of Surgical Site Infection Among Breast-Conserving Surgery Re-excisions. Ann Surg Oncol (2014) 0.86

Cost implications of the SSO-ASTRO consensus guideline on margins for breast-conserving surgery with whole breast irradiation in stage I and II invasive breast cancer. Ann Surg Oncol (2014) 0.82

Quantitative molecular phenotyping with topically applied SERS nanoparticles for intraoperative guidance of breast cancer lumpectomy. Sci Rep (2016) 0.80

Main controversies in breast cancer. World J Clin Oncol (2014) 0.80

Effect of formalin fixation on surgical margins in breast cancer surgical specimen. Int J Breast Cancer (2014) 0.79

Individualized, patient-centered application of consensus guidelines to improve the quality of breast cancer care. Int J Radiat Oncol Biol Phys (2014) 0.78

Current status of ultrasound-guided surgery in the treatment of breast cancer. World J Clin Oncol (2016) 0.78

The lobar approach to breast ultrasound imaging and surgery. J Med Ultrason (2001) (2015) 0.78

Spectrally encoded confocal microscopy for diagnosing breast cancer in excision and margin specimens. Lab Invest (2016) 0.77

In reply to Dixon and Thomas. Int J Radiat Oncol Biol Phys (2014) 0.75

Cost-effectiveness analysis of whole-mount pathology processing for patients with early breast cancer undergoing breast conservation. Curr Oncol (2016) 0.75

[Conservative treatment of breast cancer: experience of a Tunisian team]. Pan Afr Med J (2014) 0.75

Modelling the radiobiological effect of intraoperative X-ray brachytherapy for breast cancer using an air-filled spherical applicator. J Contemp Brachytherapy (2016) 0.75

Surgical margin reporting in breast conserving surgery: Does compliance with guidelines affect re-excision and mastectomy rates? Breast (2015) 0.75

Trends and controversies in multidisciplinary care of the patient with breast cancer. Curr Probl Surg (2016) 0.75

Geographical Inequalities in Surgical Treatment for Localized Female Breast Cancer, Queensland, Australia 1997-2011: Improvements over Time but Inequalities Remain. Int J Environ Res Public Health (2016) 0.75

Breast MR imaging for the assessment of residual disease following initial surgery for breast cancer with positive margins. Eur Radiol (2017) 0.75

Effects of Ionizing Irradiation on Mouse Diaphragmatic Skeletal Muscle. Front Physiol (2017) 0.75

Awareness and current knowledge of breast cancer. Biol Res (2017) 0.75

Molecular Subtypes and Local-Regional Control of Breast Cancer. Surg Oncol Clin N Am (2018) 0.75

Local therapies for breast cancer. Memo (2017) 0.75

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60

Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med (2002) 18.61

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol (2009) 17.92

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet (2011) 9.20

Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol (2007) 7.51

The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet (2008) 6.50

Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol (2006) 6.07

Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol (2010) 5.44

A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol (2008) 5.26

Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med (2010) 4.63

Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45

Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol (2012) 4.33

Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol (2009) 3.99

Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol (2004) 3.82

Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol (2011) 3.75

Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer (1985) 3.60

The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol (2008) 3.31

Variability in reexcision following breast conservation surgery. JAMA (2012) 3.26

Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol (2011) 3.22

Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA (2009) 2.64

The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer (1994) 2.43

Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol (2013) 2.35

Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol (2007) 2.32

Prone vs supine positioning for breast cancer radiotherapy. JAMA (2012) 2.32

Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol (2001) 2.28

Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol (2009) 2.26

The relationship between shaved margin and inked margin status in breast excision specimens. Cancer (1997) 2.22

Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol (1997) 2.20

Current perceptions regarding surgical margin status after breast-conserving therapy: results of a survey. Ann Surg (2005) 2.00

Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol (2011) 1.99

Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer (2009) 1.99

Pathologic predictors of early local recurrence in Stage I and II breast cancer treated by primary radiation therapy. Cancer (1984) 1.95

Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst (2004) 1.88

Margins of "lumpectomy" for breast cancer. Hum Pathol (1986) 1.86

Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer (2010) 1.85

The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J Clin Oncol (1990) 1.71

What is an adequate margin for breast-conserving surgery? Surgeon attitudes and correlates. Ann Surg Oncol (2009) 1.52

Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol (2010) 1.47

Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer (2005) 1.40

Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results. Invest Radiol (2011) 1.39

Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer (2001) 1.37

Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol (2007) 1.23

The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol (2014) 1.18

A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment, and outcomes. J Am Coll Surg (1998) 1.17

Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol (2005) 1.17

Ten-year results in 1070 patients with stages I and II breast cancer treated by conservative surgery and radiation therapy. Cancer (1995) 1.15

Pathologic findings on re-excision of the primary site in breast cancer patients considered for treatment by primary radiation therapy. Cancer (1987) 1.13

Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess (2007) 1.12

Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer (2012) 1.11

Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy. Ann Surg Oncol (2008) 1.10

Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: can radiotherapy ever be safely withheld? Radiother Oncol (2008) 1.08

The pancake phenomenon contributes to the inaccuracy of margin assessment in patients with breast cancer. Am J Surg (2002) 1.08

Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer (2004) 1.04

Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol (2011) 1.03

Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer first results of the randomized Budapest boost trial. Strahlenther Onkol (2002) 1.02

Breast-conserving therapy for triple-negative breast cancer. JAMA Surg (2014) 1.00

Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ. Arch Pathol Lab Med (2011) 0.97

Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation. Cancer (2001) 0.97

Factors determining outcome for breast-conserving irradiation with margin-directed dose escalation to the tumor bed. Int J Radiat Oncol Biol Phys (1998) 0.93

Clinical-pathologic features, long term-outcome and surgical treatment in a large series of patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). Eur J Surg Oncol (2013) 0.91

Optimal surgical treatment of invasive lobular carcinoma of the breast. Ann Surg Oncol (1998) 0.89

Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy. Cancer (2003) 0.88

Lobular carcinoma in situ as a component of breast cancer: the long-term outcome in patients treated with breast-conservation therapy. Int J Radiat Oncol Biol Phys (1998) 0.86

Outcome in breast molecular subtypes according to nodal status and surgical procedures. Am J Surg (2013) 0.86

Breast conservation therapy: the influence of molecular subtype and margins. Int J Radiat Oncol Biol Phys (2011) 0.83

Radiotherapy boost dose-escalation for invasive breast cancer after breast-conserving surgery: 2093 patients treated with a prospective margin-directed policy. Radiother Oncol (2013) 0.83

Influence of margin status on outcomes in lobular carcinoma: experience of the European Institute of Oncology. Ann Surg (2011) 0.83

Impact of the radiation boost on outcomes after breast-conserving surgery and radiation. Int J Radiat Oncol Biol Phys (2010) 0.79

In reply to Dixon and Thomas. Int J Radiat Oncol Biol Phys (2014) 0.75

Is mastectomy undertreatment for low-risk breast cancers eligible for breast-conserving therapy? Cancer (2015) 0.75